You are currently viewing a new version of our website. To view the old version click .

9 Results Found

  • Review
  • Open Access
1 Citations
1,976 Views
15 Pages

20 August 2025

IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis worldwide, with a heterogeneous clinical course that may progress to end-stage kidney disease (ESKD) in approximately 20% of patients. Despite recent advances, including the U.S....

  • Review
  • Open Access
58 Citations
10,607 Views
21 Pages

Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes

  • Vjera Ninčević,
  • Tea Omanović Kolarić,
  • Hrvoje Roguljić,
  • Tomislav Kizivat,
  • Martina Smolić and
  • Ines Bilić Ćurčić

20 November 2019

Diabetic nephropathy (DN) is one of the most perilous side effects of diabetes mellitus type 1 and type 2 (T1DM and T2DM).). It is known that sodium/glucose cotransporter 2 inhibitors (SGLT 2i) and glucagone like peptide-1 receptor agonists (GLP-1 RA...

  • Article
  • Open Access
1 Citations
2,268 Views
13 Pages

MES SV40 Cells Are Sensitive to Lipopolysaccharide, Peptidoglycan, and Poly I:C Expressing IL-36 Cytokines

  • Cesar G. Pelcastre-Rodriguez,
  • Ernesto A. Vazquez-Sanchez,
  • José M. Murrieta-Coxca,
  • Sandra Rodríguez-Martínez,
  • Juan C. Cancino-Diaz and
  • Mario E. Cancino-Diaz

7 October 2022

Mesangial cells (MC) maintain the architecture and cellular communication and indirectly join in the glomerular filtration rate for the correct functioning of the glomerulus. Consequently, these cells are activated constantly in response to changes i...

  • Review
  • Open Access
2,058 Views
19 Pages

Critical Review of the Benefit from Early Pharmacological and Dietary Support for Patients with Moderate-to-Severe (Non-Terminal) Chronic Kidney Disease

  • Charline Danneel,
  • Camille Sauvage,
  • Mohamed Nabil Hayef,
  • Véronique Desmet,
  • Murielle Surquin,
  • Joëlle Nortier and
  • Carine De Vriese

Moderate-to-severe chronic kidney disease (CKD) is a public health problem affecting hundreds of millions of people around the world. Started early, nephroprotection measures are able to prevent the degradation of renal function and are a major issue...

  • Review
  • Open Access
13 Citations
3,302 Views
12 Pages

Mechanisms Limiting Renal Tissue Protection and Repair in Glomerulonephritis

  • Andrea Angeletti,
  • Maurizio Bruschi,
  • Xuliana Kajana,
  • Sonia Spinelli,
  • Enrico Verrina,
  • Francesca Lugani,
  • Gialuca Caridi,
  • Corrado Murtas,
  • Giovanni Candiano and
  • Marco Prunotto
  • + 1 author

Glomerulonephritis are renal disorders resulting from different pathogenic mechanisms (i.e., autoimmunity, complement, inflammatory activation, etc.). Clarifying details of the pathogenic cascade is basic to limit the progression from starting inflam...

  • Review
  • Open Access
28 Citations
4,050 Views
14 Pages

Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline

  • Antonio Lardaro,
  • Ludovica Quarta,
  • Stefania Pagnotta,
  • Giorgio Sodero,
  • Sandro Mariani,
  • Maria Del Ben,
  • Giovambattista Desideri,
  • Evaristo Ettorre and
  • Francesco Baratta

Dementia is an age-related syndrome characterized by the progressive deterioration of cognition and capacity for independent living. Diabetes is often associated with cognitive decline and shares similar pathophysiological mechanisms with dementia, s...

  • Review
  • Open Access
53 Citations
11,975 Views
11 Pages

27 April 2018

A low-protein diet (LPD) can be expected to retard renal function decline in advanced stages of chronic kidney disease (CKD), including diabetic kidney disease (DKD), and is recommended in a clinical setting. Regarding the molecular mechanisms of an...

  • Review
  • Open Access
8 Citations
5,715 Views
19 Pages

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review

  • Angelica Cersosimo,
  • Andrea Drera,
  • Marianna Adamo,
  • Marco Metra and
  • Enrico Vizzardi

24 October 2024

The history of sodium-glucose cotransporter 2 inhibitors (SGLT2i) is so long and started in 1835 when Petersen extracted a compound called phlorizin from apple tree bark. About fifty years later, von Mering discovered its glucosuric properties. In th...

  • Review
  • Open Access
4,122 Views
41 Pages

Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs

  • Syed Arman Rabbani,
  • Mohamed El-Tanani,
  • Rakesh Kumar,
  • Manita Saini,
  • Yahia El-Tanani,
  • Shrestha Sharma,
  • Alaa A. A. Aljabali,
  • Eman Hajeer and
  • Manfredi Rizzo

28 July 2025

Background: Chronic Kidney Disease (CKD) is a major global health issue, with diabetes being its primary cause and cardiovascular disease contributing significantly to patient mortality. Recently, two classes of medications—sodium–glucose...